Chromosomal translocations are primary events in tumorigenesis. Those involving the mixed lineage leukaemia (MLL) gene are found in various guises and it is unclear whether MLL fusions can affect haematopoietic differentiation. We have used a model in which chromosomal translocations are generated in mice de novo by Cre-loxPmediated recombination (translocator mice) to compare the functionally relevant haematopoietic cell contexts for Mll fusions, namely pluripotent stem cells, semicommitted progenitors or committed cells. Translocations between Mll and Enl or Af9 cause myeloid neoplasias, initiating in pluripotent stem cells or multipotent myeloid progenitors. However, while Mll-Enl translocations can also cause leukaemia from T-cell progenitors, no tumours arose with Mll-Af9 translocations in the T-cell compartment. Furthermore, Mll-Enl translocations in T-cell progenitors can cause lineage reassignment into myeloid tumours. Therefore, a permissive cellular environment is required for oncogenicity of Mll-associated translocations and Mll fusions can influence haematopoietic lineage commitment.
Introduction
Cancer generally arises from a single cell that acquires a somatic mutation in a gene capable of eliciting a cell division property and/or immortalisation (Vogelstein and Kinzler, 2004) . This initiating cell also gains the characteristic of self-renewal but may or may not be the cell that has the self-maintenance capacity of the putative cancer stem cell (Reya et al, 2001) . Chromosomal translocations are primary events in cancer, and create an immortal lineage that provides cells for secondary mutations to give frank malignancy. Leukaemia and lymphomas arise within a hierarchy of progenitor, committed or terminally differentiated cells. These are exemplified, respectively, by chronic myeloid leukaemia (CML), Burkitt's lymphoma and multiple myeloma. Among the somatic mutations that characterise these tumours, recurrent chromosomal translocations are generally found at presentation of disease. Moreover, chromosomal translocations are often the sole cytogenetic chromosomal abnormality at such time (see http://cgap.nci.nih.gov/Chromosomes/ Mitelman). Important studies of concordant leukaemias in monozygotic twins have shown the presence of identical MLL-AF4 (mixed lineage leukaemia) chromosomal translocations but with different immunoglobulin gene rearrangements, demonstrating the in utero origin of this leukaemic precursor cell .
Chromosomal translocations involving the MLL gene typify gene fusion. MLL is involved in multifarious chromosomal translocations in human acute leukaemias with adverse prognosis. The MLL gene is located on human chromosome 11, band q23, and is associated with translocations, inversions and duplications of 11q23 (see Daser and Rabbitts, 2004) . MLL is a homologue of the Drosophila Trx gene and Hox genes are necessary for Mll-fusion-induced leukaemia in mice Kumar et al, 2004) . Thus, presumably MLL-fusion proteins confer deregulation on HOX genes, in turn as a consequence of chromosomal abnormalities of chromosome 11q23. MLL protein can bind directly to HOXA9 and HOXC8 promoters (Milne et al, 2002; Nakamura et al, 2002) and can act as a histone methyltransferase (methylating Lys4 of histone H3) (Sobulo et al, 1997; Birke et al, 2002; Milne et al, 2002; Xia et al, 2003; Hess, 2004; Yokoyama et al, 2004) .
MLL-associated translocations represent a cross-section of possible associations found in acute leukaemias. There are more than 30 different known chromosome partners involving MLL, each appearing to result in a fusion of MLL with a gene from a different chromosomal region (see Daser and Rabbitts, 2004) . A notable feature of MLL translocation leukaemias is that the main fusion partners (i.e. AF4, AF9, ENL, ELL) are found in tumours of either lymphoid lineage (AF4) or myeloid lineage (AF9 or ELL) or of both lineages (ENL). It is not known if MLL fusions are simply oncogenic in any haematopoietic cell, either progenitor or committed cells. Furthermore, it is still unclear if an MLL-fusion protein has an instructive property on a cell, driving differentiation into specific haematopoietic lineages. Mouse models have begun to address these issues. Studies of retroviral transduction of bone marrow stem cells with viruses expressing MLL fusions (Ayton and Cleary, 2001; So et al, 2003; Zeisig et al, 2003) , gene targeting knock-in models expressing Mll-AF9 fusion (Corral et al, 1996; Dobson et al, 1999) or a translocator mouse model, in which de novo translocations of Mll-Enl occur , show that haematopoietic stem cells (HSC) are targets for Mll fusions. In addition, retroviral transduction of semicommitted, common myeloid progenitors (CMP) (Miyamoto et al, 2002) has shown that similar leukaemias result from these progenitors as from transduced bone marrow HSC . Recently, an Mll-CBP conditional knock-in model indicated targeting of granulocyte-macrophage progenitors (Wang et al, 2005) .
In the translocator mouse model (Buchholz et al, 2000; Collins et al, 2000) , chromosomal translocations are made de novo in a cell-specific manner, using Cre-loxP recombination in vivo (Smith et al, 1995; van Deursen et al, 1995) . Chromosomal translocations can thus be generated as primary genetic changes, initially in the absence of any other changes and at predetermined stages of haematopoiesis. Using Lmo2-Cre to express Cre recombinase, chromosomal translocations were made in pluripotent stem cells, and MllEnl fusion resulted in myeloid leukaemia .
We have now applied the translocator approach using an LckCre allele that specifically causes expression of Cre recombinase in T cells and their progenitors Codrington et al, 2005) . We find that Mll-Enl fusions can be oncogenic in the lymphoid lineage as in human leukaemias. However, when Mll-Af9 translocations are induced in similar T-cell populations via Lck-Cre expression, no leukaemias arose, although Mll-Af9 translocations in uncommitted progenitors do induce myeloid leukaemias. Therefore, Mll fusions are not necessarily oncogenic in any haematopoietic cell. Furthermore, the Mll-associated leukaemic precursor cell expressing the Mll-Enl fusion can undergo lineage reassignment from the lymphoid lineage into myeloid lineage.
Results

Mll-Enl and Mll-Af9 fusions cause myeloid neoplasias in translocator mice
Mice have been described (Collins et al, 2000; Forster et al, 2003) carrying Mll, Enl or Af9 genes with loxP sites within the appropriate introns for Cre-mediated chromosomal translocations equivalent to those found in human leukaemias (the loxP sites were introduced by homologous recombination in embryonic stem (ES) cells and these targeted ES cells were used to generate mice). These mice were designated translocator mice . The Mll, Enl or Af9 alleles are diagrammatically shown in Figure 1A , indicating the intronic location of the loxP sites. Cre recombinase can recognise these sites and cause interchromosomal translocations resulting in translocation t(9;4) (Mll-Af9) or t(9;17) (Mll-Enl) ( Figure 1A ).
The effects of targeting the Mll chromosomal translocations to haematopoietic cells of differing maturities, and comparative assessment of chromosomal translocations between Mll and different fusion partners such as Enl or Af9 genes, were analysed with these Mll; Enl or Mll; Af9 translocators. We used a strain of mice with Cre recombinase expression under the control of the Lck promoter (Wildin et al, 1995) , which restricts Cre expression to the T-cell lineage Codrington et al, 2005) , or the Lmo2 promoter, which works in HSC (Yamada et al, 1998; McCormack et al, 2003; Schlaeger et al, 2004) . Cohorts of 20 mice were established with Mll plus Enl or Mll plus Af9 loxP alleles and carrying the Lck-Cre transgene (designated, respectively, Mll; Enl; Lck-Cre or Mll; Af9; Lck-Cre mice). In addition, a cohort of Mll; Af9; Lmo2-Cre mice was studied.
Comparable control groups with only the Lck-Cre allele, the Mll plus Enl loxP or Mll plus Af9 loxP alleles were also studied. All mice were monitored for possible adverse effects. Out of the 20 Mll; Enl; Lck-Cre mice, 18 developed haematopoietic neoplasms within 18 months ( Figure 1B ) and all the mice in the Mll; Af9; Lmo2-Cre cohort developed haematological malignancies. No haematological malignancies were observed in the mice of the Mll; Af9; Lck-Cre cohort.
Mll; Enl; Lck-Cre translocators develop either lymphoid or myeloid tumours Haematopoietic neoplasias in the Mll-Enl translocators were dependent on Lck-Cre and in Mll-Af9 translocators on Lmo2-Cre, supporting a mandatory role for chromosomal translocations in neoplasia in these mice. The presence of chromosomal translocations in the cells characterising the (Collins et al, 2000; Forster et al, 2003) . LoxP sites were introduced, by homologous recombination in ES cells, into introns of mouse Mll, Enl or Af9, corresponding to the human introns where chromosomal translocations are typically found. Specific cells in mice carrying loxP sites in both Mll and Enl or Mll and Af9 genes can undergo chromosomal translocations, mediated by Cre recombinase, to create fusion genes analogous to those of human leukaemias, as indicated. (B) Survival curves for translocator mice. Cohorts of 20 translocator mice expressing Cre under the control of Lck or Lmo2 promoters were analysed over a period of about 1.5 years.
haematological malignancies was verified by either genomic DNA filter hybridisation to detect the chromosomal fusion point or by fluorescence in situ hybridisation (FISH) (Figure 2 ). Exemplification is presented in Figure 2 , showing filter hybridisation of Mll; Enl; Lck-Cre or Mll; Af9; Lmo2-Cre translocator DNA (tumour, thymus and liver biopsy) with 5 0 Mll, 3 0 Mll (Figure 2A and B), 3 0 Enl probes ( Figure 2C ) or a 3 0 Af9 probe ( Figure 2D ). The translocated alleles were observed in all three tissues examined, even in the liver where some sections have high numbers of cells with the chromosomal translocation. An independent assessment of the presence of chromosomal translocations in the tumour cells was obtained by FISH. Metaphase spreads from spleen cells of tumour mice were hybridised with whole chromosome paints for chromosome 9 (Mll, green) and chromosome 17 (Enl, red) ( Figure 2C ) or chromosome 4 (Af9, red; Figure 2D ). In addition, expression of the Mll-fusion genes was confirmed by RT-PCR analysis of RNA prepared from cell lines established from tumours (see below). We could detect the relevant Mll-fusion mRNA in RNA prepared from Mll-AF9 knock-in, Mll; Enl; Lmo2-Cre and Mll; Af9; Lmo2-Cre translocator mice ( Figure 2E ). The cells present in the tumours, therefore, express Mll-fusion mRNA, carry reciprocal chromosomal translocations and the malignancies are caused (Corral et al, 1996; Dobson et al, 1999) , Mll; Enl; Lmo2-Cre translocators and Mll; Af9; Lmo2-Cre translocators (this paper). RNA was made and converted to cDNA for RT-PCR amplification with primers spanning junctions of Mll and Enl or Af9 RNA sequences as indicated. Total bone marrow RNA from a wild-type mouse was used as a negative control for cDNA lacking Mll-fusion sequences and RT-PCR with actin primers was used for quality control of cDNA. C: no template (H 2 O) control; BM: bone marrow; ki: knock-in.
by the Mll-fusion protein since they are dependent on the presence of Mll-loxP, Enl-loxP or Af9-loxP plus the Cre-expressing alleles.
Post-mortem analysis revealed splenomegaly typifying the haematological malignancy in both the Mll; Enl; Lck-Cre and Mll; Af9; Lmo2-Cre translocators, due to an almost total repopulation of the spleen with malignant cells (Figure 3 ) represented by loss of distinct white and red pulp architecture. In Mll; Af9; Lmo2-Cre translocators, perivascular deposits of these same cells are evident with associated infiltration of large areas of the liver (a similar picture was found with kidney and lung, data not shown) and involvement of lymph nodes. These features, together with myeloid surface marker expression on the neoplastic cells ( Figure 4 and Supplementary Table 1B), suggest that these mice consistently develop myeloid lineage malignancies. Blood smears show circulating leukaemic cells of various maturities, including a large proportion of well-differentiated cells. By the Bethesda classification of nonlymphoid tumours , these mice have myeloproliferative (MPD)-like myeloid leukaemia. Blood smears of the Mll; Enl; Lck-Cre translocator mice showed little evidence of circulating leukaemic cells (Figure 3 ), unlike the Mll; Enl; Lmo2-Cre translocators previously described and the Mll; Af9; Lmo2-Cre translocators described here ( Figures 3 and 4) , both of which have a similar MPD-like myeloid leukaemia. This distinction may reflect differences in the leukaemic precursors in the translocator models since the chromosomal translocations are caused by Cre expression controlled by different Cre alleles.
A total of 90% of the Mll; Enl; Lck-Cre translocator mice developed haematological malignancy in the 18-month period of the experimental analysis. The haematological malignancy in these translocators was analysed by surface protein expression profile using FACS analysis to determine the major cell types from spleens of mice with splenomegaly. Figure 4 and Supplementary Table 1 embody findings with the Mll; Enl; Lck-Cre translocators compared with Mll; Af9; Lmo2-Cre translocator mice. Unlike the uniform finding of MPD-like myeloid leukaemia in Mll; Af9; Lmo2-Cre translocator mice described here and Mll; Enl; Lmo2-Cre mice , the neoplasias found in Mll; Enl; Lck-Cre mice were either of the T-cell or the myeloid lineage. Examples are shown in Figure 4 , where a Mac-1/Gr-1 double positive Figure 3 Histopathology of tumours from Mll-Enl and Mll-Af9 translocator mice. Tissues were fixed in 10% formalin and wax embedded prior to generation of histological sections. The sections were stained with H&E and photographed at Â 40 magnification. May-Grü nwald-Giemsa (MGG)-stained blood films and sections shown are from an Mll; Af9; Lmo2-Cre translocator mouse (top row), from an Mll; Enl; Lck-Cre translocator mouse (middle row) or from a C57BL/6 wild-type mouse (bottom row). myeloid tumour is compared with a CD4-positive, CD8-negative T-cell tumour. Data for 18 tumours in the Mll; Enl; LckCre cohort are shown in Supplementary Table 1A . In addition to the cell surface marker phenotype, examination of histopathology defined the tumours as T-cell lineage. The characteristics of these T-cell tumours (including T-cell receptor Tcrb gene rearrangements; see Figure 5 ) were splenomegaly, lymphadenopathy without enlargement of thymus and expression of T-cell receptor-associated CD4 and/or CD8 molecules. This classifies the tumours as mature T-cell neoplasms, specifically small T-cell lymphoma (STL) according to the Bethesda classification .
While some Mll; Enl; Lck-Cre mice developed STL, others developed tumours expressing myeloid markers (Figure 4 and Supplementary Table 1) , which showed few, poorly differentiated cells in blood, myeloid cell histology in spleen and had infiltrates of neoplastic cells in the liver and kidneys. These criteria demonstrated the presence of myeloid leukaemia without maturation in these mice, by the Bethesda classification of nonlymphoid neoplasms .
All Mll; Enl; Lck-Cre tumours have a footprint of Rag V-D-J recombinase activity
The finding of T-cell or myeloid tumours in Mll; Enl; Lck-Cre mice is intriguing because of the specific expression of the Lck-Cre transgene in T cells . This implies that both the STL and the myeloid neoplasias in the Mll; Enl; Lck-Cre translocator mice have their origin within cells of the lymphoid lineage. The precursors of the STLs were presumably committed to T-cell differentiation, whereas the myeloid leukaemias could have arisen from early lymphoid progenitor cells retaining various differentiation options, allowing reassignment of cellular commitment, as suggested by early studies of human acute myeloid leukaemia (AML) (Boehm et al, 1987a, b; Adriaansen et al, 1991) . The corollary of Lck-Cre expression, which initiates in immature thymocytes, is Mll; Enl; Lck-Cre translocators should undergo We examined the genomic DNA of the Mll; Enl; Lck-Cre translocator splenic tumours with Tcr b chain and Igh probes. All except one (tumour 11, which showed a myeloid surface marker pattern of splenic tumour cells) showed rearrangement of the Tcr b chain and/or Igh probes ( Figure 5 and Supplementary Table 1A) . Most exhibited bi-allelic rearrangements, and some showed four rearranged bands implying that the tumour is either not clonal or comprises two distinct populations of cells (e.g. Figure 5B , lane 4). This is not a random rearrangement phenomenon as neither the myeloid lineage tumours from Mll; Enl; Lmo2-Cre mice (F Cano and TH Rabbitts, unpublished) nor splenic tumours from the Mll; Af9; Lmo2-Cre translocators described here showed Tcr b chain or Igh gene alterations (14 Mll; Af9; Lmo2-Cre tumours were compared and seven are shown for reference in Figure  5A , D and E). Thus, the cells that constitute all the Mll; Enl; Lck-Cre translocator splenic tumours have passed through a differentiation stage during which the Rag recombinase genes were expressed and the Rag proteins were actively performing their function of V-D-J recombination in these precursors. This suggests an intermediate stage of T-lymphoid differentiation in all these tumours, even those that present with a myeloid lineage phenotype.
Cell-specific effects of Mll-Af9 chromosomal translocations
Our observations with Mll-Enl translocator mice showed that haematopoietic malignancies ensue if de novo chromosomal translocations are induced by Cre expression from the Lmo2-Cre allele or from the Lck-Cre allele (this paper). We previously found that mice expressing an Mll-AF9 fusion knock-in allele developed haematological malignancies with a myeloid phenotype (Corral et al, 1996; Dobson et al, 1999) . We have compared the effects of Mll; Af9 translocator mice made with Lck-Cre or Lmo2-Cre alleles. A cohort of Mll; Af9; Lck-Cre translocators was studied for an 18-month period. Surprisingly, no signs of ill health or postmortem abnormalities were found in these mice at the 18-month point. This contrasts with malignancies in the cohort of Mll; Af9; Lmo2-Cre translocators, which all succumbed to leukaemia within about 1 year ( Figure 1B ). These latter mice have a similar pathology to the Mll; Enl; Lmo2-Cre translocators, showing MPD-like myeloid leukaemia. The tumour cells carry reciprocal chromosomal translocations as judged by filter hybridisation with 5 0 or 3 0 Mll DNA probes ( Figure 2B ) or with a 3 0 Af9 probe ( Figure 2D ). In addition, FISH analysis of spleen cells from the tumour-bearing mice showed the reciprocal chromosome ( Figure 2D ) and the typically diploid state of the tumours.
Thus, while Mll; Af9; Lmo2-Cre translocators can develop leukaemias, Mll; Af9; Lck-Cre do not. It is possible that chromosome territory within mouse lymphoid cells specifically precludes chromosomal translocations between the Mll and Af9 genes. We investigated the presence of Mll and Af9 interchromosomal translocations in asymptomatic mice using a genomic PCR assay dependent on the ability to amplify a product if Mll and Af9 sequences were abutted following translocation (Figure 6 ). Pups were identified from 8-day postnatal litters of Mll; Enl; Lck-Cre, Mll; Af9; Lmo2-Cre or Mll; Af9; Lck-Cre genotype. Thymus and bone marrow DNA was prepared and used in nested PCR analysis for the presence of chromosomal translocations. In each case, five pups of appropriate genotypes were used. Examination of DNA from Mll; Enl; Lck-Cre pups showed that one of the five had detectable Mll-Enl translocations in both thymus and bone marrow DNA ( Figure 6A ). By contrast, all five Mll; Af9; Lck-Cre pups showed chromosomal translocations in thymic DNA but none had any detectable in bone marrow ( Figure 6C ). This striking difference is despite the fact that Mll; Af9; Lck-Cre translocators do not develop leukaemias whereas essentially all Mll; Enl; Lck-Cre do. Finally, all the Mll; Af9; Lmo2-Cre pups had translocations in both thymus and bone marrow ( Figure 6B ) consistent with the rapid leukaemogenesis in these mice. Therefore, despite the absence of tumorigenesis, Mll-Af9 chromosomal translocations do occur in Lck-Cre-expressing cells and furthermore, they occur in T cells very early in the life of the Mll; Af9; Lck-Cre mice.
The expression of Mll-Af9 fusion mRNA was demonstrated by RT-PCR with RNA-cDNA made from Mll; Af9; Lck-Cre mice at 3 or 6 months of age ( Figure 6D ). We found that RNA from the spleen, thymus and bone marrow, even at 6 months, contained Mll-Af9 transcripts, whereas other tissues such as the kidney did not. Thus, sustained expression of the chromosomal translocation occurs in Mll; Af9; Lck-Cre mice. These results suggest that Mll-Af9 is inert in committed T cells.
Mll-Af9 and Mll-Enl translocator myeloid tumours are transplantable
The ability of the Mll-fusion-dependent tumours to undergo independent growth was assessed by establishment of tissue culture lines from Mll-AF9 knock-in mice (Corral et al, 1996; Dobson et al, 1999) and Mll; Enl; Lmo2-Cre translocators (Collins et al, 2000; Forster et al, 2003) . We have been unable to make lines from Mll; Enl; Lck-Cre translocators, irrespective of the lymphoid or myeloid phenotype. The tumorigenicity of the other lines was tested in a nude mouse assay in which cells were inoculated subcutaneously and tumour growth was assessed. All the lines developed into tumours in a high proportion of recipients, with latencies less than 3 weeks (Table I ). In addition, the retention of either the Mll-AF9 knock-in allele or the Mll-Af9 or Mll-Enl chromosomal translocation was confirmed by filter hybridisation (data not shown).
Discussion
The translocator model recapitulates analogous events in human cancers
The translocator mouse model (Smith et al, 1995; van Deursen et al, 1995; Buchholz et al, 2000; Collins et al, 2000) can recapitulate chromosomal translocations found in human tumours by allowing cell-specific de novo chromosomal translocations to take place. This means that reciprocal translocations can be engineered in vivo for the first time. We have shown that Mll-associated translocations can be induced by Cre recombinase between two pairs of chromosomes (i.e. between chromosomes 9 and 4 or between chromosomes 9 and 17) in similar cell types, as well as in distinct lineages. Chromosomes 4 and 17 therefore seem equally accessible to translocate with chromosome 9, indicating that chromosome territory might not impinge too heavily on the ability of translocation between different Mll partners. In addition to mimicking the ability of MLL to fuse with various partners and cause leukaemia, the outcome of the mouse Mll-Enl and Mll-Af9 chromosomal translocations parallels the tumour phenotypes found in humans, where the former is seen in T-cell tumours or in myeloid tumours whereas MLL-AF9 is almost exclusively seen in myeloid tumours.
Leukaemic precursor cells in Mll-associated leukaemias
Chromosomal translocations are primary events in haematopoietic tumours (Rowley, 1999) and the putative self-renewing leukaemic stem cell (LSC) must carry the chromosomal translocation. The oncogenicity of Mll-fusion proteins in Figure 6 Chromosomal translocations are present in Mll; Af9; Lck-Cre translocators by postnatal day 8 and Mll-Af9 expressed at 6 months. (A-C) Bone marrow (BM) and thymus (Thy) genomic DNA was prepared from 8-day-old pups (five littermates for each genotype) from Mll; Af9; Lck-Cre or Mll; Enl; Lck-Cre translocators. PCR was performed for 70 cycles using nested primers to amplify either (A) Mll plus Enl (MG1 þ EG1, followed by MN þ EN; Forster et al, 2003) or (B, C) Mll plus Af9 primers (1a þ 1b, followed by 2a þ 2b; Collins et al, 2000) . Positive controls were performed on DNA from Mll; Af9 or Mll; Enl translocator splenic tumours (indicated as AML) using 35 cycles of amplification, and negative controls were performed, using 70 cycles of amplification, on DNA prepared from spleens of P8 litter mates of Mll; Af9 or Mll; Enl mice without the Cre gene (indicated as CreÀ). Quality control of DNA was determined by PCR amplification of the Lmo2 gene with primers B5 and B3 using 35 cycles of amplification. Primer locations are diagrammatically shown. Bands corresponding to amplified products are indicated as follows: ME: Mll-Enl junction; MA: Mll-Af9 junction; L2: Lmo2 gene product. (D) Litters of Mll; Af9; Lck-Cre mice, including Mll; Af9 controls lacking Cre gene, were established and at 3 or 6 months, RNA was prepared from the spleen, thymus, kidney and bone marrow (latter at 6 months only). RT-PCR was carried out with primers from exon 10 of Mll or exon 9 of Af9 to detect RNA products of the Mll-Af9 translocated fusion allele. The double-headed arrow indicates the gel band corresponding to the product of this translocated allele. Mll-Af9 fusion mRNA transcript was present in the spleen and thymus at 3 months and in addition detected in these tissues and in bone marrow at 6 months of translocator mice. M: fX174 HaeIII-digested DNA markers; þ ve: RT-PCR product from an Mll-Af9 leukaemia produced in Mll; Af9; Lmo2-Cre mice; Àve: RT-PCR in the absence of template; BM: bone marrow. Cell lines from either Mll-AF9 knock-in or Mll-Enl translocator mice were cultured in the presence of growth factors (see Materials and methods) and 1-5 Â10 6 cells were injected into the flanks of 6-to 8-week-old female MF1 nude mice. Tumours were resected at approximately 1.5 cm size and post-tumour growth evaluation was conducted for genotype, presence of the relevant translocation alleles and surface marker expression. Number (No.) of tumours is expressed as fraction of tumours/number of injection sites. All lines were negative with antibodies recognising Sca1, C-kit, Ter119, CD4, CD8, Thy1, CD25 and B220. different cells of haematopoiesis has been evaluated using knock-in alleles (Corral et al, 1996; Dobson et al, 1999 Dobson et al, , 2000 Wang et al, 2005) , or retroviral delivery of MLL fusions to HSC (Slany et al, 1998; Lavau et al, 2000; Deguchi et al, 2003; So et al, 2003; Zeisig et al, 2003) or translocator mice . These demonstrate that tumours develop with a differentiated phenotype. Furthermore, transduction of Mll-Enl-expressing retroviruses into purified GMP progenitor cells showed that leukaemias could also develop from these .
In studies of MLL-AF4 chromosomal translocations in monozygotic twins, leukaemias were found that arose with clonal origin in utero but with different immunoglobulin rearrangements in the leukaemias at presentation . This provides strong evidence that the MLL-AF4 chromosomal translocations were primary in the LSC and that MLL-AF4 can exert an effect on pluripotent HSC. However, the fusion protein may also have molecular consequences for later cells, which are no longer pluripotent. We show in our translocator model that the primary effects of Mll-Enl fusion can occur in noncommitted cells or cells that are partially or fully committed to the T-lymphocyte lineage. Thus, Mll fusions do not need the environment of noncommitted cell to be oncogenic, suggesting that MLL translocation-associated leukaemia in man is not a mandatory stem cell leukaemia.
Mll-fusion proteins require a permissive environment for oncogenicity
The Mll-Af9 fusion appears to be unable to support tumorigenesis in T-lymphopoiesis whereas it is a potent inducer of myeloid leukaemias. The absence of Mll; Af9; Lck-Creinduced leukaemias is not due to the lack of translocations or expression of Mll-Af9 fusion mRNA in Mll; Af9; Lck-Cre nonleukaemic mice (Figure 6 ). Therefore, Mll-Af9 is inert in the multipotent progenitors destined to produce the T-cell lineage. This 'inertia' (depicted in Figure 7 ) may be due to the nonresponsiveness of target genes to lineage activation by Mll-Af9, or secondary mutations necessary for Mll-Af9 complementation do not typically occur in T cells or cofactors needed for Mll-Af9 function do not exist in T cells. The first possibility raises intriguing questions about the nature of MLL-fusion protein target genes, namely the possibility of common and specific target genes for MLL fusions in haematopoietic cells. If all MLL fusions have common effects on the transcriptome (e.g. control of HOX gene expression), we should anticipate the same consequence of having Mll-Enl and Mll-Af9 translocations in T cells. Our data therefore suggest separation of MLL-fusion protein function into distinct parts, one being related to cell phenotype control (instructive function and controlling putative Mll-fusion-specific target genes) and another to development of oncogenic phenotype.
The Lck-Cre expression causes Mll-Af9 translocations but not leukaemia
We have shown that Mll-Enl is an effective oncogene when chromosomal translocations are caused by Cre recombinase made from an Lck-Cre allele. Virtually all the Mll; Enl; Lck-Cre mice developed leukaemia (Figure 1 ) but the phenotypes of these tumours were disparate, only a proportion being T-cell neoplasias and the majority myeloid tumours. Crucially, irrespective of the cell lineage, the tumours had detectable rearrangements of immunoglobulin and/or T-cell receptor genes (95% of tumours). This footprint of Rag gene expression means that the precursors of all these tumours have been through a stage during which Rag recombination takes place, which is a feature of lymphoid development (Gellert, 2002) . This critical finding places the initiating chromosomal translocation event for the myeloid tumours of Mll; Enl; Lck-Cre mice within cells after the common lymphocyte precursor stage, implying that these are noncommitted lymphoid progenitors (see below).
An additional fundamental issue is the specificity of the Lck-Cre allele for Cre expression in the T-cell lineage as misexpression in progenitors might explain the myeloid tumours in Mll; Enl; Lck-Cre translocators. Several lines of evidence demonstrate that Lck-Cre is T-cell specific. Only those cells designated as being within the T-cell pathway (from DN1 cells onwards, which is just a stage before endogenous Lck activity is apparent; Wolfer et al, 2001, No tumours arose when Mll-Af9 chromosomal translocations were induced by Lck-Cre expression, even though both chromosomal translocations and Mll-Af9 fusion mRNA could be detected. Thus, when Mll translocations are induced in the pluripotent stem cells or in the multipotent myeloid progenitors using Lmo2-Cre, myeloid malignancies arise (this paper . A more complex situation was observed when the chromosomal translocations between Mll and Enl genes were induced by Lck-Cre-controlled expression of Cre recombinase. In this case, either T-cell malignancies or myeloid leukaemias appeared; however, in both types, the leukaemia progenitors had arisen from cells that had expressed functional Rag V-D-J recombinase. Thus, the myeloid malignancies of the Mll; Enl; Lck-Cre translocator mice appear to arise from cells that have undergone a lineage reassignment from a semicommitted, Rag þ lymphoid cell to a myeloid cell. This effect may occur by reprogramming the transcriptome of cells with the chromosomal translocations to realigning differentiation into myeloid from lymphoid status. HSC: haematopoietic stem cells; CMP: common myeloid progenitors; GMP: granulocyte-monocyte precursors; MEP: megakaryocyte-erythrocyte precursors; CLP: common lymphoid progenitors.
2002) showed Cre-dependent deletion of a floxed chromosomal segment of the Lmo2 gene as a reporter or activation of the lacZ gene in the ROSA locus with the Lck-Cre-controlled Cre (Codrington et al, 2005) . There was no evidence of Lck-Cre activity in progenitors or in purified Mac-1-or Gr-1-positive cells (using a radiolabelled hybridisation assay for sensitive detection of deletion of a loxP-flanked reporter gene and the other direct detection of b-gal-positive cells (Codrington et al, 2005) ). The analysis has been extended by the use of the ROSA-YFP reporter line (Srinivas et al, 2001 ) in which no progenitor or myeloid cells were found coexpressing relevant surface markers and YFP (markers were CD34, Sca1, Ter119, Mac-1 or Gr-1) (LF Drynan & TH Rabbitts, unpublished) . Further, no Cre activity could be detected after selection of cells expressing B-cell markers (CD19, B220, IgM, IgD or IgG).
A critical biological control that provides a very powerful assessment of the specific association of Cre activity with T-cell lineage precursors or mature T cells is our observation that no tumours arose in translocator mice with Mll-Af9 translocations induced by Lck-Cre. Our previous work with Mll-AF9 knock-in mice (Corral et al, 1996; Dobson et al, 1999) , and with Mll-Af9 translocators in this paper, shows that this fusion creates a very potent myeloid oncogenic protein. In addition, we show that Mll-Af9 chromosomal translocations occur in all thymuses of Mll;Af9; Lck-Cre mice tested as early as 8 days after birth and the fusion gene is expressed at least to 6 months of age ( Figure 6 ). This shows that these translocator T cells can undergo translocation and there is no obvious clonal deletion of the cells carrying the expressed Mll-Af9 fusion allele. If the myeloid tumours in the Mll; Enl; Lck-Cre arose because the Lck-Cre allele was expressing at some level in myeloid progenitors or in some occasional progenitor cell, we would expect myeloid tumours in the Mll; Af9; Lck-Cre translocators. A final piece of evidence of a T-cell progenitor origin for the myeloid tumours in Mll; Enl; Lck-Cre translocators is that they have Tcr/Igh gene rearrangements, unlike the myeloid tumours arising in progenitors such as those made in Mll; Af9; Lmo2-Cre or Mll; Enl; Lmo2-Cre translocator mice. We conclude that the LckCre allele is specific for the T-cell lineage and that the myeloid tumours originate in cells after the CLP stage in the Mll; Enl; Lck-Cre translocator mice.
Mll-Enl can cause lineage reassignment
We have found that either T-cell or myeloid type leukaemias arise from Mll-Enl chromosomal translocations mediated by the T-cell-specific Cre recombinase made from our Lck-Cre transgenic mouse . These findings suggest that expression of Mll-Enl in immature T-cell precursors elicits reprogramming of the cells into the myeloid lineage. A process of lineage reassignment in human leukaemias has already been indicated by previous observations that AML often have rearranged antigen receptor genes (Boehm et al, 1987a, b; Adriaansen et al, 1991) . Direct experimental support for reprogramming of lymphoid precursors into myeloid cells has been provided by ectopic expression of v-raf (Klinken et al, 1988) or CEB/P (Xie et al, 2004) , indicating that aberrant gene expression can force cells to respond to different developmental programmes. These data indicate that the boundaries in haematopoietic lineage assignment may be blurred, as strict development along individual pathways is subvertable (Klinken et al, 1988; Xie et al, 2004) . The ability of Mll-Enl to reassign lymphoid cells to myeloid lineage reflects a pathogenic subversion of lineage commitment and supports an instructive function to this (and possibly other) MLL fusion, in accordance with the master gene model for the effects of oncogene activation following chromosomal translocations in acute leukaemias (Rabbitts, 1991) . The model that emerges is of a noncommitted T-cell progenitor that would normally have only one fate, namely to develop into a mature thymocyte (i.e. after Rag recombinase expression). If an Mll-Enl translocation occurs in this early, noncommitted T-cell progenitor, the influence of the Mll-Enl fusion is reassignment of lineage into the myeloid pathway. Conversely, if the translocations occur after the cell has progressed sufficiently far along the T-cell differentiation pathway, the neoplastic cell can only present as a T-cell leukaemia. The molecular events by which this lineage reassignment occurs will be interesting, as it should identify molecular targets of instructive MLL-fusion protein function distinct from other putative common functions.
Materials and methods
Analysis of translocator mouse strains
Mouse lines carrying loxP sites in either an Mll intron, an Af9 intron or an Enl intron have been described (Collins et al, 2000; Forster et al, 2003) . The general structure of these alleles is summarised in Figure 1A . Mice expressing Cre recombinase either under the control of the Lmo2 or the Lck promoter were bred with those with Mll, Enl or Af9 loxP alleles to generate cohorts of 20 mice for each genotype. Mice carrying Mll and Enl or Af9 alleles with loxP sites with or without a Cre allele are designated respectively (Mll; Enl; Lmo2-Cre), (Mll; Enl; Lck-Cre) or (Mll; Enl) or (Mll; Af9; Lmo2-Cre), (Mll; Af9; Lck-Cre) or (Mll; Af9). At the signs of ill health, post mortem was carried out and tissues were removed as needed. Histological sections (4 mm in thickness) were made from fixed tissue using wax embedding and were stained with haematoxylin and eosin (H&E). Flow cytometry was conducted using a FACScaliber and surface proteins were detected with fluorescent antibodies (BD-Pharmingen).
Detection of chromosomal translocations was carried out using Southern filter hybridisation or FISH as described (LeFranc et al, 1986; Forster et al, 2003) . Filters were incubated for 24 h with 32 Plabelled probes at 651C in a 3 Â SSC buffer and washed at 651C with 0.1 Â SCC and 0.1% SDS. Hybridisation signal was detected with pre-fogged X-ray films at À701C with intensifying screens. FISH analysis was carried out with metaphase spreads of spleen cells and metaphase spreads were painted with whole chromosome paints for chromosome 9 (green, Mll chromosome), 17 (red, Enl chromosome) or 4 (red, Af9 chromosome) (Cambio).
Antigen receptor gene rearrangements were detected by Southern filter hybridisation. Splenic tumour genomic DNA or CCB ES cell DNA was restriction digested, fractionated and transferred to nylon membranes followed by hybridisation to either a mouse Igh probe (Neuberger and Williams, 1986) or T-cell receptor probes (Cb1 or Jb2) (Malissen et al, 1984) . DNA was cleaved with either HindIII or EcoRI for Igh gene status or HindIII for Tcr gene status.
Detection of Mll chromosomal translocations and mRNA in nonleukaemic mice
Genomic PCR was carried out using nested primers and 0.5 mg genomic DNA per initial 25 ml PCR reactions. A 1 ml portion of this reaction was used with nested primers, again in 25 ml reaction. PCR reactions were initially denatured at 951C for 2 min followed by 35 cycles comprising 951C for 1 min, 651C for 1 min and 721C for 1 min with a final 721C step for 10 min. The PCR primers flanking the MllEnl translocation junction were MG1 þ EG1 followed by nested primers MN þ EN (Forster et al, 2003) . Primers flanking the Mll-Af9
